Ray Dalio's BCRX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 638,054 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $6.07 M, representing 0.03% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Ray Dalio has maintained this position in BCRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 402,482 shares. Largest reduction occurred in Q4 2025, reducing 175,931 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +402,482 | Add 170.85% | 638,054 | $9.52 |
| Q4 2025 | -175,931 | Reduce 42.75% | 235,572 | $7.80 |
| Q3 2025 | +411,503 | New Buy | 411,503 | $7.59 |
Ray Dalio's BioCryst Pharmaceuticals Investment FAQs
Ray Dalio first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q3 2025, acquiring 411,503 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held BioCryst Pharmaceuticals, Inc. (BCRX) for 3 quarters since Q3 2025.
Ray Dalio's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q3 2025, adding 411,503 shares worth $3.12 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 638,054 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $6.07 M.
As of the Q1 2026 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 638,054 shares, as reported at the end of Q1 2026.